OTLK OUTLOOK THERAPEUTICS INC
Company Analysis
Latest News
🔴 OTLK down 5% today following recent rally fueled by FDA BLA acceptance and Nasdaq compliance
• OTLK is trading 5% down at $1.60 today, likely due to profit-taking after its recent rally. • The rally was driven by the FDA's acceptance of the resubmitted...
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
Outlook Therapeutics, Inc. has received notification from Nasdaq confirming that it has regained compliance with the minimum bid price requirement for...
🟢 OTLK makes sharp 10.9% jump
OTLK is trading at $1.78, up 10.9% versus the comparison close of $1.61 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 OTLK is trading 7.1% up today as it rebounds from profit-taking following FDA BLA acceptance
OTLK is trading 7.1% up at $1.73, rebounding after yesterday’s profit-taking dip that followed a sharp rally driven by regulatory progress. • The primary...
🔴 OTLK is trading 5.1% down today as traders take profits following its recent FDA-driven rally
OTLK is trading at $1.59 (down 5.1%) as the stock experiences a pullback following a significant rally sparked by positive regulatory news. • The recent surge...
🔴 OTLK is trading 5.2% down today as the recent FDA-driven rally cools
OTLK is trading at $1.61 (-5.24%) today as the stock gives back part of its recent gains following the FDA's acceptance of its resubmitted BLA. • The FDA has...
Outlook Therapeutics Nears Its Make-or-Break FDA Moment — But Can a Cash-Strapped Micro-Cap Actually Sell Its Eye Drug?
Shares of Outlook Therapeutics edged up 1.8% in pre-market to $1.73, extending a rally that has seen the stock roughly triple from its March lows. The...
🟢 OTLK is trading 1.8% up today after FDA sets July 2026 decision date for Lytenava
OTLK is trading 1.8% up at $1.73 in pre-market trading following enthusiasm around the FDA’s July 29, 2026, PDUFA date for its eye drug Lytenava. • The FDA...
🟢 OTLK is trading 1.8% up today after FDA sets July decision date for Lytenava
OTLK is trading at $1.73 (+1.8%) in pre-market, continuing a rally sparked by the FDA setting a July decision date for its eye drug, Lytenava. • The FDA...
🔴 OTLK is trading 6.3% down today on profit-taking after a recent multi-day surge
OTLK is trading 6.3% down at $1.72 as investors lock in profits following a sharp multi-session rally. • The stock recently experienced significant upward...
🟢 OTLK makes sharp 11.4% jump
OTLK is trading at $1.76, up 11.4% versus the comparison close of $1.58 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 OUTLOOK THERAPEUTICS INC makes sharp 13.3% drop
OTLK is trading at $1.43, down 13.3% versus the comparison close of $1.65 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 OUTLOOK THERAPEUTICS INC is trading 7% up today after FDA accepts BLA resubmission for ONS-5010
OUTLOOK THERAPEUTICS INC is trading at $1.68 (7% up) today after the FDA accepted the company’s resubmitted BLA for ONS-5010 for wet AMD. • The FDA assigned a...
🟢 OUTLOOK THERAPEUTICS INC is trading 23.7% up today after FDA accepts BLA resubmission with July PDUFA date
OUTLOOK THERAPEUTICS INC is trading 23.7% up today at $1.44 after announcing that the FDA accepted its resubmitted Biologics License Application (BLA) for...
FDA Accepts BLA Resubmission for Wet AMD Drug, Sets July 29 PDUFA Date
Outlook Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted Biologics License Application (BLA) for ONS-5010...
🟢 OUTLOOK THERAPEUTICS INC is trading 6.6% up today after FDA appeal win for ONS-5010 and price target hike
OUTLOOK THERAPEUTICS INC is trading at $1.30 (up 6.6%) after a key FDA appeal win that enables the resubmission of its Biologics License Application (BLA) for...
🟢 OUTLOOK THERAPEUTICS INC is trading 6.6% up today after FDA appeal win and price target hike
• The company announced a significant regulatory update, with the FDA granting its appeal following a Formal Dispute Resolution process, paving the way for a...
Outlook Therapeutics Target Hiked to $10, Fueled by EU Drug Approval
Ascendiant Capital maintained its Buy rating for Outlook Therapeutics on June 11, 2026. The firm increased its price target to $10.00 from $6.00. This...
🟢 OUTLOOK THERAPEUTICS INC is trading 18.2% up today on analyst upgrade and positive FDA momentum
OUTLOOK THERAPEUTICS INC is trading 18.2% up at $1.30 following a significant price-target hike from Ascendiant Capital and continued positive momentum from...
🟢 OUTLOOK THERAPEUTICS INC is trading 10.91% up today after Ascendiant Capital raised its price target to $10
OUTLOOK THERAPEUTICS INC is trading at $1.22 (+10.91%) in after-hours action following a significant price-target increase and continued market momentum. •...